Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Titel:
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Auteur:
Younes, Anas Berdeja, Jesus G Patel, Manish R Flinn, Ian Gerecitano, John F Neelapu, Sattva S Kelly, Kevin R Copeland, Amanda R Akins, Amy Clancy, Myles S Gong, Lucy Wang, Jing Ma, Anna Viner, Jaye L Oki, Yasuhiro